Media about us

• Russian partnerships: Pfizer and NovaMedica break ground on aseptic plant

  05 June 2017 Dan Stanton / InPharma Technologist

  
  Pfizer and NovaMedica have broken ground on a manufacturing facility in Kaluga set to supply the Russian market with sterile injectable drugs. The ceremony this week comes five months after global pharma firm Pfizer announced it had completed the transfer of the rights and technologies for the production of over.

• The three factors crucial to effectiveness in healthcare

  05 June 2017

  

  SPIEF-2017. Panel discussion "The three factors crucial to effectiveness in healthcare". “The problem and task is to boost the system’s performance within the budget available for now. That does not mean the system needs no more money, that means spending must be efficient,” said Leonid Melamed, Chairman of the Board of Directors, Team Drive.

• Plant to produce Pfizer sterile injectables for Russia gets under way

  01 June 2017 Eric Palmer / Fierce Pharma

  

  Russia's NovaMedica is building a new sterile injectables plant in the Kaluga region where it will produce 30 of Pfizer’s sterile injected generic meds for the local market.

• Construction of a new pharmaceutical plant started in Vorsino Industrial Park

  01 June 2017 GMP News

  

  On May 30, Vorsino Industrial Park in the Kaluga region hosted an official ceremony to mark the start of construction of an advanced biopharmaceutical production facility owned by NovaMedica LLC (a RUSNANO investment project).

• Construction of Pfizer-sponsored pharmaceutical factory starts in Russia

  31 May 2017 Construction.ru

  

  A ground-breaking ceremony of a pharmaceutical factory was held on Tuesday in Vorsino technology park located near the Russian city of Kaluga. American company Pfizer is an investor of the enterprise's building project. The main partner of the project is NovaMedica, a portfolio company of the Russian government-owned company Rusnano engaged in the development of nanotechnology.

• Russia – USA. The bilateral business interest in investment remains high.

  29 May 2017 TASS

  

  In their first talks, Russia’s President Vladimir Putin and the US President Donald Trump noted the importance of restoring full-scale economic partnership, with due account of the fact that in 2016 Russian-American projects started and continued virtually across the entire economy. The numbers include the US investments in Russian export-oriented and import-substituting industries. A number of such projects began in 2016 alone, with Pfizer’s pharmaceutical factory and Novamedica Company in the Kaluga Region among them.

• US Companies in Russia Regularly Confirm Determination to Stay - Embassy

  29 May 2017 Sputnik

  

  Minister-Counselor of the Russian Embassy in the United States Denis Gonchar said in anterview with Sputnik on Monday that American companies working in Russia regularly confirm that they are not going to leave the country. One of his examples that US global pharmaceutical corporation Pfizer and Russian pharmaceutical company NovaMedica signed a strategic partnership agreement, including the construction of a manufacturing plant in the Vorsino industrial park for production of more than 30 vital medicinal products and the work of joint technical laboratories in Moscow.

• Syndax shares soar as lead drug clears a mid-stage cancer drug study hurdle

  17 May 2017 John Carroll / Endpoints News

  Briggs Morrison has good reason today to be glad he left the Big Pharma R&D world behind at AstraZeneca and switched to biotech. The CEO of Waltham, MA-based Syndax reported that the company’s lead drug in combination with Merck’s Keytruda cleared its first big hurdle in Phase II and will now transition into the second phase of the study.

• Epic Sciences nets $40M for cancer liquid biopsy

  02 May 2017 Amirah Al Idrus / FierceBiotech

  

  Epic Sciences raised $40 million in a Series D round, which it will use to ramp up clinical studies of its liquid biopsy tests that identify cancer patients who will benefit from specific treatments.

• Biopharma just can’t get enough of Epic Sciences

  02 May 2017 Juliet Preston / MedCityNews

  

  Epic Sciences has to be one of the coolest kids on the biopharma block, with a new $40 million Series D financing round, a whopping 42 industry partnerships and over 200 clinical trials in the works, all built around its novel liquid biopsy platform. For a team of just 70, the San Diego, California startup is doing pretty well.